Abstract
Background
In vitro and in vivo studies demonstrated the antiviral efficacy of nerve growth factor (NGF) and its cyto-protective effect in herpes simplex virus (HSV)-infected cells. The aims of this study were to evaluate the role of endogenous NGF in HSV corneal infection, and the effects of topical NGF treatment on herpetic keratitis.
Methods
Herpetic keratitis was induced in 40 rabbits with the HSV-1 McKrae strain. Animals were divided into four groups, and treated with topical neutralizing anti-NGF antibodies, NGF, acyclovir or balanced salt solution (BSS) respectively. The clinical course of HSV keratitis was evaluated and scored by slit-lamp examination. In addition, biochemical (immunohistochemistry for glycoprotein D) and molecular (nested PCR for glycoprotein D) analyses were carried out to estimate viral replication.
Results
Treatment with anti-NGF antibodies induced a more severe keratitis associated with increased biochemical and molecular markers of active viral replication. Two animals in this group developed lethal HSV encephalitis. Conversely, topical treatment with NGF induced a significant amelioration of clinical and laboratory parameters when compared to the BSS treated group (control). No significant differences were observed between NGF- and acyclovir-treated groups.
Conclusions
This study demonstrated the crucial role of endogenous NGF in herpetic keratitis. The comparable effects of NGF and acyclovir confirm the antiviral activity of NGF, and indicate a potential use of topical NGF in herpetic keratitis.
Similar content being viewed by others
References
Akbar AN, Lord JM, Salmon M (2000) IFN-alpha and IFN-beta: a link between immune memory and chronic inflammation. Immunol Today 21:337–342
Akova YA, Onat M, Duman S (1999) Efficacy of low-dose and long-term oral acyclovir therapy after penetrating keratoplasty for herpes simplex heratitis. Ocul Immunol Inflamm 7:51–60
Aloe L (1987) Intraocular herpes simplex virus injection in neonatal rats induces sympathetic nerve cell destruction: effect of nerve growth factor. Int J Dev Neurosci 5:357–366
Anand BS, Hill JM, Dey S, Maruyama K, Bhattacharjee PS, Myles ME, Nashed YE, Mitra AK (2003) In vivo antiviral efficacy of a dipeptide Acyclovir prodrug, val-val-Acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model. IOVS 44:2529–2534
Arffa RC (1991) Epithelial diseases. In: Arffa RC (ed.) Grayson’s diseases of the cornea, 3rd edn. Mosby Inc, St. Louis
Aurelius E, Johansson B, Skoldenberg B, Staland A, Forsgren M (1991) Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid. Lancet 337:189–192
Barney NP, Foster CS (1994) A prospective randomized trial of oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Cornea 13:232–236
Barouch R, Kazimirsky G, Appel E, Brodie C (2001) Nerve growth factor regulates TNF-alpha production in mouse macrophages via MAP kinase activation. J Leukoc Biol 69:1019–1026
Biswas S, Suresh P, Bonshek RE, Corbitt G, Tullo AB, Ridgway AE (2000) Graft failure in human donor corneas due to transmission of herpes simplex virus. Br J Ophthalmol 84:701–705
Bocchini V, Angeletti PU (1969) The nerve growth factor: purification as a 30,000-molecular-weight protein. Proc Natl Acad Sci USA 64:787–794
Bonini S, Lambiase A, Rama P, Caprioglio G, Aloe L (2000) Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology 107:1347–1351
Bonneau RH, Sheridan JF, Feng N, Glaser R (1991) Stress-induced suppression of herpes simplex virus (HSV)-specific cytotoxic T lymphocyte and natural killer cell activity and enhancement of acute pathogenesis following local HSV infection. Brain Behav Immun 5:170–192
Coassin M, Lambiase A, Costa N, De Gregorio A, Sgrulletta R, Sacchetti M, Aloe L, Bonini S (2005) Efficacy of topical nerve growth factor treatment in dogs affected by dry eye. Graefes Arch Clin Exp Ophthalmol 243:151–155
Cocchi F, Fusco D, Menotti L, Gianni T, Eisenberg RJ, Cohen GH, Campanelli-Fiume G (2004) The solubile ectodomain of herpes simplex virus gD contains a membrane-proximal pro-fusion domain and suffices to mediate virus entry. Proc Natl Acad Sci USA 101:7445–7450
Cockerham G (2001) Primary graft failure caused by herpes simplex virus type 1. Cornea 20:774–775
Cook ML, Bastone VB, Stevens JG (1974) Evidence that neurons harbor latent herpes simplex virus. Infect Immun 9:946–951
Cook SD (1992) Herpes simplex virus in the eye. Br J Ophthalmol 76:365–366
De Maria A, Tundo P, Romano A, Grima P (1995) Anti-HSV-1 herpes vaccination by LUPIDON H: preliminary results. Adv Exp Med Biol 371B:1599–1600
Dicou E, Nerriere V, Labropoulou V (1991) Naturally occurring antibodies against nerve growth factor in human and rabbit sera: comparison between control and herpes simplex virus-infected patients. J Neuroimmunol 34:153–158
Ehrhard PB, Ganter U, Stalder A, Bauer J, Otten U (1993) Expression of functional trk protooncogene in human monocytes. Proc Natl Acad Sci USA 90:5423–5427
Gee AP, Boyle MD, Munger KL, Lawman MJ, Young M (1983) Nerve growth factor: stimulation of polymorphonuclear leukocyte chemotaxis in vitro. Proc Natl Acad Sci USA 80:7215–7218
Heise MT, Virgin HW (1995) The T-cell-independent role of gamma interferon and tumor necrosis factor alpha in macrophage activation during murine cytomegalovirus and herpes simplex virus infections. J Virol 69:904–909
Herpetic Eye Disease Study Group (2000) Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Arch Ophthalmol 118:1030–1036
Hill JM, Garza HH Jr, Helmy MF, Cook SD, Osborne PA, Johnson EM Jr, Thompson HW, Green LC, O’Callaghan RJ, Gebhardt BM (1997) Nerve growth factor antibody stimulates reactivation of ocular herpes simplex virus type 1 in latently infected rabbits. J Neurovirology 3:206–211
Johnson GL, Limon L, Trikha G, Wall H (1994) Acute renal failure and neurotoxicity following oral acyclovir. Ann Pharmacother 28:460–463
Lalani AS, Barrett JW, McFadden G (2000) Modulating chemokines: more lessons from viruses. Immunol Today 21:100–106
Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L (1998) Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med 338:1174–1180
Lambiase A, Manni L, Bonini S, Rama P, Micera A, Aloe L (2000) Nerve growth factor promotes corneal healing: structural, biochemical, and molecular analyses of rat and human corneas. Invest Ophthalmol Vis Sci 41:1063–1069
Lambiase A, Bonini S, Rama P, Bonini S, Aloe L (2000) Antiinflammatory and healing properties of nerve growth factor in immune corneal ulcers with stromal melting. Arch Ophthalmol 118:1446–1449
Laycock KA, Brady RH, Lee SF, Osborne PA, Johnson EM, Pepose JS (1994) The role of nerve growth factor in modulating herpes simplex virus reactivation in vivo. Graefes Arch Clin Exp Ophthalmol 232:421–425
Levi-Montalcini R (1987) The nerve growth factor 35 years later. Science 237:1154–1162
Levi-Montalcini R, Aloe L, Alleva E (1990) A role for nerve growth factor in nervous, endocrine and immune system. Progress In Neuroendocrinimmunology 3:1–10
Matsuda H, Coughlin MD, Bienenstock J, Denburg JA (1988) Nerve growth factor promotes human hemopoietic colony growth and differentiation. Proc Natl Acad Sci USA 85:6508–6512
McLennan JL, Darby G (1980) Herpes simplex virus latency: the cellular location of virus in dorsal root ganglia and the fate of the infected cell following activation. J Gen Virol 51:233–243
Moyes AL, Sugar A, Musch DC, Barnes RD (1994) Antiviral therapy after penetrating keratoplasty for herpes simplex keratitis. Arch Ophthalmol 112:601–607
Nja A, Purves D (1978) The effects of nerve growth factor and its antiserum on synapses in the superior cervical ganglion of the guinea-pig. J Physiol 277:53–75
Otten U, Ehrhard P, Peck R (1989) Nerve growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci USA 86:10059–10063
Perry AK, Chen G, Zheng D, Tang H, Cheng G (2005) The host type I interferon response to viral and bacterial infections. Cell Res 15:407–422
Pivetti-Pezzi P, Accorinti M, Colabelli-Gisoldi RA, Pirraglia MP, Sirianni MC (1999) Herpes simplex virus vaccine in recurrent herpetic ocular infection. Cornea 18:47–51
Price RW, Schmitz J (1978) Reactivation of latent herpes simplex virus infection in autonomic nervous system by postganglionic neurectomy. Infect Immun 19:523–532
Purves D, Nja A (1976) Effect of nerve growth factor on synaptic depression following axotomy. Nature 260:535–536
Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson D (1993) Programmed cell death and the control of cell survival: lessons from the nervous system. Science 262:695–700
Rajcani J, Vojvodova A (1998) The role of herpes simplex glycoproteins in the virus replication cycle. Acta Virol 42:103–118
Remeijer L, Osterhaus A, Verjans G (2004) Human herpes simplex virus keratitis: the pathogenesis revisited. Ocul Immunol Inflamm 12:255–285
Sawtell NM, Thompson RL (1992) Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J Virol 66:2150–2156
Sedgwick JD, Riminton DS, Cyster JG, Korner H (2000) Tumor necrosis factor: a master-regulator of leukocyte movement. Immunol Today 21:110–113
Smith RL, Pizer LI, Johnson EM Jr, Wilcox CL (1992) Activation of second-messenger pathways reactivates latent herpes simplex virus in neuronal cultures. Virol 188:311–318
Tambasco FP, Cohen EJ, Nguyen LH, Rapuano CJ, Laibson PR (1999) Oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Arch Ophthalmol 117:445–449
The Herpetic Eye Disease Study Group (1998) Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med 339:300–306
Thoenen H, Barde YA (1980) Physiology of nerve growth factor. Physiol Rev 60:1284–1335
Thorpe LW, Perez-Polo JR (1987) The influence of nerve growth factor on the in vitro proliferative response of rat spleen lymphocytes. J Neurosci Res 18:134–139
Ungheri D, Verini MA, Ganceff L, Mazue G, Carminati P (1993) Antiviral activity of nerve growth factor in vitro. Drugs Exp Clin Res 19:151–157
Vandepapeliere P (2002) Therapeutic vaccination against chronic viral infections. Lancet Infect Dis 2:353–367
Walz MA, Price RW, Notkins AL (1974) Latent ganglionic infection with herpes simplex virus types 1 and 2: viral reactivation in vivo after neurectomy. Science 184:1185–1187
Wilcox CL, Johnson EM (1987) Nerve growth factor deprivation results in the reactivation of latent herpes simplex virus in vitro. J Virol 61:2311–2315
Wilcox CL, Johnson EM Jr (1988) Characterization of nerve growth factor-dependent herpes simplex virus latency in neurons in vitro. J Virol 62:393–399
Wilcox CL, Smith RL, Freed CR, Johnson EM Jr (1990) Nerve growth factor-dependence of herpes simplex virus latency in peripheral sympathetic and sensory neurons in vitro. J Neurosci 10:1268–1275
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lambiase, A., Coassin, M., Costa, N. et al. Topical treatment with nerve growth factor in an animal model of herpetic keratitis. Graefes Arch Clin Exp Ophthalmol 246, 121–127 (2008). https://doi.org/10.1007/s00417-007-0593-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-007-0593-6